Cortexin

Both are brain-derived polypeptide preparations, but they differ in several ways. Cortexin is derived specifically from the cerebral cortex of cattle (and young pigs), while Cerebrolysin is derived from whole porcine brain tissue. Cortexin is provided as a lyophilized powder requiring reconstitution and is administered only intramuscularly (up to 10 mg), while Cerebrolysin comes as a ready-to-use solution and can be given both intramuscularly and intravenously in much larger volumes (up to 50 ml). Cortexin is primarily available in Russia and CIS countries from GEROPHARM, while Cerebrolysin (by EVER Pharma, Austria) is approved in over 40 countries. Preclinical studies suggest comparable neuroprotective efficacy between the two preparations.

Cortexin is approved and widely used in Russia and some CIS (Commonwealth of Independent States) countries. It is not approved by the FDA (United States), EMA (European Union), or most other Western regulatory agencies. It may be available through some international online pharmacies, but procurement and use outside approved markets carries regulatory and safety risks. The majority of clinical research on Cortexin has been published in Russian-language medical journals.

Yes, Cortexin has been used in pediatric neurology in Russia for conditions including cerebral palsy, developmental delays, epilepsy (as adjunctive therapy), and cognitive impairment in children. The pediatric dosage is based on body weight: 5 mg IM daily for children under 20 kg, and 10 mg IM daily for children over 20 kg, given for a 10-day treatment course. Cortexin has demonstrated efficacy and safety as adjunctive therapy in children with cerebral palsy combined with epilepsy in Russian clinical studies.

Cortexin is provided as a lyophilized (freeze-dried) white or slightly yellow powder in sealed glass vials. Before use, the powder must be dissolved in 1-2 ml of 0.9% sodium chloride solution (normal saline) or water for injection. The reconstituted solution is then administered by intramuscular injection, typically into the deltoid or gluteal muscle. The injection should be given in the morning to avoid potential sleep disturbance. The reconstituted solution must be used immediately and cannot be stored.

Animal studies have demonstrated that the neuroprotective and cognitive benefits of Cortexin persist for at least 10 days after the last injection, and clinical experience suggests effects can last for weeks to months. However, for chronic conditions such as cerebrovascular disease and cognitive impairment, repeated treatment courses every 3-6 months are recommended to maintain and build upon therapeutic gains. The multicenter CORNELia study showed sustained cognitive improvements at the 30-day assessment point after treatment initiation.

The evidence base for Cortexin includes multicenter observational studies (such as the CORNELia study with 801 patients), comparative animal studies, and extensive Russian clinical experience. However, it lacks large-scale, randomized, double-blind, placebo-controlled trials published in major international peer-reviewed journals. Most research has been published in Russian medical journals (primarily Zhurnal Nevrologii i Psikhiatrii). While the Russian clinical evidence is substantial, the limited availability of English-language studies and the absence of Western regulatory approval mean that Cortexin's evidence base is not considered strong by international standards.